Literature DB >> 12571520

Population survey of CCR5 delta32, CCR5 m303, CCR2b 64I, and SDF1 3'A allele frequencies in indigenous Chinese healthy individuals, and in HIV-1-infected and HIV-1-uninfected individuals in HIV-1 risk groups.

Fu-Sheng Wang1, Wei-Guo Hong, Yunzhen Cao, Ming-Xu Liu, Lei Jin, Liang-Ping Hu, Zhe Wang, Tie-Jian Feng, Jing Hou, Bing Zhang, Ming Shi, Dong-Ping Xu, Zhou-Yun Lei, Bo Wang, Zheng-Dong Liu, Jun-Jie Ye, Lin Peng, Ya Qiu, Cheryl Winkler.   

Abstract

The aim of this study is to determine in indigenous Chinese ethnic groups the frequencies of the chemokine (SDF1 3'A) and chemokine receptors (CCR5 delta32, CCR5 m303, and CCR2b 64I) HIV-1/AIDS restriction alleles. The study includes two cohorts; the first comprised 3165 indigenous healthy subjects representing eight ethnic groups: Han (n = 1406), Uygur (n = 316), Mongolia (n = 134), Hui (n = 386), Tibetan (n = 330), Zhuang (n = 378), Dai (n = 101), and Jingbo (n =114). The second cohort consisted of 330 HIV-1-infected (86 subjects infected by sexual transmission and 198 subjects infected by HIV-1-contaminated blood or by sharing injection equipment; the remaining 46 subjects said nothing about HIV-1 transmission) and 474 HIV-1-uninfected Han Chinese belonging to one of two HIV-1 high-risk groups: intravenous drug users (n = 215) and individuals with sexually transmitted diseases (n = 259). Genotypes for the four genes were obtained using PCR (CCR5 delta32) or PCR-restriction fragment length polymorphism. Randomly selected amplified PCR products were further confirmed by direct DNA sequencing. The variant allele frequencies were determined to be 0% to 3.48% for CCR5 delta32, 0% for CCR5 m303, 16.23% to 28.79% for CCR2b 64I, and 17.70% to 27.76% for SDF1 3'A in Chinese healthy individuals from eight ethnic groups. These findings show that allele frequencies differ among the eight Chinese ethnic groups for CCR5 delta32, CCR2b 64I, and SDF1 3'A and that the CCR5 m303 and CCR5 delta32 mutant alleles were absent or infrequent in Chinese, which may be helpful for studies of specific anti-HIV-1 vaccine trials and coreceptor inhibitor drug targets in Chinese populations. Furthermore, we observed no significant differences in allele or genotypic frequencies between HIV-1-infected and HIV-1-uninfected groups from the Han ethnic group. Our finding is the first reporting that there is likely no effect of the examined polymorphisms in our study on HIV-1 transmission in the Chinese Han population, However, the genetic effects of these and other AIDS-modifying polymorphisms on the pathogenesis and clinical outcome of HIV-1/AIDS diseases is under investigation in Chinese populations.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12571520     DOI: 10.1097/00126334-200302010-00002

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  14 in total

1.  Impact of CCR2 and SDF1 polymorphisms on disease progression in HIV-infected subjects in Thailand.

Authors:  Palanee Ammaranond; Sayompoo Sanguansitthianan; Poonlaph Phaengchomduan; Chanachai Sae-Lee; Sirimarn Mardkhumchan
Journal:  J Clin Lab Anal       Date:  2013-01       Impact factor: 2.352

2.  Association analysis and allelic distribution of deletion in CC chemokine receptor 5 gene (CCR5Δ32) among breast cancer patients of Pakistan.

Authors:  Faria Fatima; Saima Saleem; Abdul Hameed; Ghulam Haider; Syed Aqib Ali Zaidi; Madiha Kanwal; Sitwat Zehra; Abid Azhar
Journal:  Mol Biol Rep       Date:  2019-03-08       Impact factor: 2.316

3.  CCR5Δ32 (rs333) polymorphism is associated with the susceptibility to systemic lupus erythematosus in female Brazilian patients.

Authors:  Thiago Hissnauer Leal Baltus; Ana Paula Kallaur; Marcell Alysson Batisti Lozovoy; Helena Kaminami Morimoto; Francieli Delongui; Daniela Frizon Alfieri; Tatiane Mayumi Veiga Iriyoda; Isaias Dichi; Andrea Name Colado Simão; Edna Maria Vissoci Reiche
Journal:  Rheumatol Int       Date:  2015-06-14       Impact factor: 2.631

4.  Gene polymorphisms in CCR5, CCR2, CX3CR1, SDF-1 and RANTES in exposed but uninfected partners of HIV-1 infected individuals in North India.

Authors:  Pallikuth Suresh; Ajay Wanchu; Ravinder Kaur Sachdeva; Archana Bhatnagar
Journal:  J Clin Immunol       Date:  2006-07-25       Impact factor: 8.317

5.  Role of chemokine and cytokine polymorphisms in the progression of HIV-1 disease.

Authors:  Supriya D Mahajan; Anardi Agosto-Mojica; Ravikumar Aalinkeel; Jessica L Reynolds; Bindukumar B Nair; Donald E Sykes; Jeffery Martinez; Joshua Adams; Neha Singh; Zale Bernstein; Chiu-bin Hsiao; Stanley A Schwartz
Journal:  Biochem Biophys Res Commun       Date:  2010-04-21       Impact factor: 3.575

6.  Transplanted endothelial cells repopulate the liver endothelium and correct the phenotype of hemophilia A mice.

Authors:  Antonia Follenzi; Daniel Benten; Phyllis Novikoff; Louisa Faulkner; Sanj Raut; Sanjeev Gupta
Journal:  J Clin Invest       Date:  2008-03       Impact factor: 14.808

7.  Effect of CCR5-Δ32 heterozygosity on HIV-1 susceptibility: a meta-analysis.

Authors:  Sijie Liu; Chuijin Kong; Jie Wu; Hao Ying; Huanzhang Zhu
Journal:  PLoS One       Date:  2012-04-04       Impact factor: 3.240

8.  Acquired but reversible loss of erythrocyte complement receptor 1 (CR1, CD35) and its longitudinal alteration in patients with severe acute respiratory syndrome.

Authors:  F S Wang; F L Chu; L Jin; Y G Li; Z Zhang; D Xu; M Shi; H Wu; J-M Moulds
Journal:  Clin Exp Immunol       Date:  2005-01       Impact factor: 4.330

9.  Analysis of Social and Genetic Factors Influencing Heterosexual Transmission of HIV within Serodiscordant Couples in the Henan Cohort.

Authors:  Qian Zhu; Peng Zhu; Yilei Zhang; Jie Li; Xuejun Ma; Ning Li; Qi Wang; Xiujuan Xue; Le Luo; Zizhao Li; Huijun Z Ring; Brian Z Ring; Li Su
Journal:  PLoS One       Date:  2015-06-11       Impact factor: 3.240

10.  CCR2-64I and CCR5Delta32 Polymorphisms in Korean Patients with Myasthenia Gravis.

Authors:  Hyun Sook Kim; Dae-Seong Kim; Eun Young Lee; Il-Nam Sunwoo; Young-Chul Choi
Journal:  J Clin Neurol       Date:  2007-09-20       Impact factor: 3.077

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.